ZYMEWORKS INC. (ZYME) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
23/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseZYME / S&P 4.39% / 15.20% |
LoseZYME / S&P -69.78% / 15.00% |
WinZYME / S&P 106.12% / 50.40% |
| 2026-Q10/3 |
LoseZYME / S&P -4.90% / -4.33% |
LoseZYME / S&P -12.98% / 11.30% |
LoseZYME / S&P -8.67% / 27.70% |
| 2025-Q42/3 |
WinZYME / S&P 54.16% / 2.65% |
WinZYME / S&P 38.87% / 9.00% |
LoseZYME / S&P -33.33% / 13.40% |
| 2025-Q32/3 |
WinZYME / S&P 36.10% / 8.12% |
WinZYME / S&P 116.21% / 4.61% |
LoseZYME / S&P -42.95% / 13.45% |
| 2025-Q21/3 |
LoseZYME / S&P 5.37% / 10.94% |
WinZYME / S&P 95.94% / 4.83% |
LoseZYME / S&P -35.10% / 10.63% |
| 2025-Q11/3 |
LoseZYME / S&P -18.65% / -4.27% |
WinZYME / S&P 85.05% / 4.98% |
LoseZYME / S&P -15.73% / 10.57% |
| 2024-Q41/3 |
WinZYME / S&P 16.65% / 2.41% |
LoseZYME / S&P 0.38% / 5.25% |
LoseZYME / S&P -6.36% / 6.15% |
| 2024-Q31/3 |
WinZYME / S&P 47.47% / 5.89% |
LoseZYME / S&P -86.52% / 5.89% |
LoseZYME / S&P -146.27% / 6.11% |
| 2024-Q20/3 |
LoseZYME / S&P -19.11% / 4.28% |
LoseZYME / S&P -85.99% / 5.38% |
LoseZYME / S&P -151.89% / 5.12% |
| 2024-Q10/3 |
LoseZYME / S&P 1.25% / 10.56% |
LoseZYME / S&P -88.69% / 5.71% |
LoseZYME / S&P -165.93% / 5.59% |
| 2023-Q41/3 |
WinZYME / S&P 63.88% / 11.69% |
LoseZYME / S&P -81.57% / 6.81% |
LoseZYME / S&P -192.02% / 7.78% |
| 2023-Q31/3 |
LoseZYME / S&P -26.62% / -3.27% |
WinZYME / S&P 1445.86% / 7.52% |
LoseZYME / S&P -184.07% / -5.03% |
| 2023-Q21/3 |
LoseZYME / S&P -4.42% / 8.74% |
WinZYME / S&P 1315.75% / 9.50% |
LoseZYME / S&P -166.74% / -8.57% |
| 2023-Q11/3 |
WinZYME / S&P 15.01% / 7.50% |
LoseZYME / S&P ZYME unavailable / 10.77% |
LoseZYME / S&P ZYME unavailable / -15.69% |
| 2022-Q41/3 |
WinZYME / S&P 27.80% / 7.56% |
LoseZYME / S&P ZYME unavailable / 11.88% |
LoseZYME / S&P ZYME unavailable / -17.99% |
| 2022-Q31/3 |
WinZYME / S&P 16.04% / -4.88% |
LoseZYME / S&P ZYME unavailable / 13.47% |
LoseZYME / S&P ZYME unavailable / -1.41% |
| 2022-Q20/3 |
LoseZYME / S&P -19.08% / -16.10% |
LoseZYME / S&P ZYME unavailable / 13.71% |
LoseZYME / S&P ZYME unavailable / 11.04% |
| 2022-Q10/3 |
LoseZYME / S&P -60.04% / -4.60% |
LoseZYME / S&P ZYME unavailable / 15.97% |
LoseZYME / S&P ZYME unavailable / 42.23% |
| 2021-Q40/3 |
LoseZYME / S&P -43.56% / 11.03% |
LoseZYME / S&P ZYME unavailable / 15.00% |
LoseZYME / S&P ZYME unavailable / 96.40% |
| 2021-Q30/3 |
LoseZYME / S&P -16.29% / 0.58% |
LoseZYME / S&P ZYME unavailable / 10.77% |
LoseZYME / S&P ZYME unavailable / 69.42% |
| 2021-Q21/3 |
WinZYME / S&P 9.85% / 8.55% |
LoseZYME / S&P ZYME unavailable / 6.58% |
LoseZYME / S&P ZYME unavailable / 51.81% |
| 2021-Q10/3 |
LoseZYME / S&P -33.18% / 6.17% |
LoseZYME / S&P ZYME unavailable / -1.06% |
LoseZYME / S&P ZYME unavailable / 7.39% |
| 2020-Q40/3 |
LoseZYME / S&P 1.46% / 12.15% |
LoseZYME / S&P ZYME unavailable / -3.72% |
LoseZYME / S&P ZYME unavailable / -33.42% |
| 2020-Q31/3 |
WinZYME / S&P 29.14% / 8.93% |
LoseZYME / S&P ZYME unavailable / -2.04% |
LoseZYME / S&P ZYME unavailable / -27.10% |
| 2020-Q20/3 |
LoseZYME / S&P 1.69% / 20.54% |
LoseZYME / S&P ZYME unavailable / -0.46% |
LoseZYME / S&P ZYME unavailable / -27.11% |
| 2020-Q10/3 |
LoseZYME / S&P -21.98% / -19.60% |
LoseZYME / S&P ZYME unavailable / 3.47% |
LoseZYME / S&P ZYME unavailable / -14.75% |
| 2019-Q41/3 |
WinZYME / S&P 83.31% / 9.07% |
LoseZYME / S&P ZYME unavailable / 5.36% |
LoseZYME / S&P ZYME unavailable / 2.99% |
| 2019-Q31/3 |
WinZYME / S&P 12.73% / 1.70% |
LoseZYME / S&P ZYME unavailable / 5.02% |
LoseZYME / S&P ZYME unavailable / 0.21% |
| 2019-Q21/3 |
WinZYME / S&P 35.97% / 4.30% |
LoseZYME / S&P ZYME unavailable / 6.64% |
LoseZYME / S&P ZYME unavailable / 8.65% |
| 2019-Q10/3 |
LoseZYME / S&P 10.22% / 13.65% |
LoseZYME / S&P ZYME unavailable / 8.12% |
LoseZYME / S&P ZYME unavailable / 14.29% |
| 2018-Q41/3 |
WinZYME / S&P -6.50% / -13.52% |
LoseZYME / S&P ZYME unavailable / 9.05% |
LoseZYME / S&P ZYME unavailable / 18.23% |
| 2018-Q30/3 |
LoseZYME / S&P 6.22% / 7.71% |
LoseZYME / S&P ZYME unavailable / 10.21% |
LoseZYME / S&P ZYME unavailable / 19.06% |
| 2018-Q21/3 |
WinZYME / S&P 22.96% / 3.43% |
LoseZYME / S&P ZYME unavailable / 9.03% |
LoseZYME / S&P ZYME unavailable / 14.46% |
| 2018-Q11/3 |
WinZYME / S&P 58.30% / -0.76% |
LoseZYME / S&P ZYME unavailable / 7.68% |
LoseZYME / S&P ZYME unavailable / 12.46% |
| 2017-Q40/3 |
LoseZYME / S&P -4.85% / 6.64% |
LoseZYME / S&P ZYME unavailable / 7.03% |
LoseZYME / S&P ZYME unavailable / 13.82% |
| 2017-Q30/3 |
LoseZYME / S&P -4.43% / 4.48% |
LoseZYME / S&P ZYME unavailable / 5.68% |
LoseZYME / S&P ZYME unavailable / 17.57% |
| 2017-Q20/3 |
LoseZYME / S&P ZYME unavailable / 3.09% |
LoseZYME / S&P ZYME unavailable / 4.83% |
LoseZYME / S&P ZYME unavailable / 17.74% |
| 2017-Q10/3 |
LoseZYME / S&P ZYME unavailable / 6.07% |
LoseZYME / S&P ZYME unavailable / 3.67% |
LoseZYME / S&P ZYME unavailable / 13.32% |
| 2016-Q40/3 |
LoseZYME / S&P ZYME unavailable / 3.82% |
LoseZYME / S&P ZYME unavailable / 2.09% |
LoseZYME / S&P ZYME unavailable / 7.05% |
| 2016-Q30/3 |
LoseZYME / S&P ZYME unavailable / 3.85% |
LoseZYME / S&P ZYME unavailable / 0.20% |
LoseZYME / S&P ZYME unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ZYME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 95.88% | 20.78% |
| Annualized return | 95.88% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ZYME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -12.20% | 83.14% |
| Annualized return | -2.57% | 12.86% |
10Y · 2017-04-28 to 2026-08-27
| Metric | ZYME total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 123.15% | 319.30% |
| Annualized return | 8.36% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |